ID

22392

Beschrijving

Study to Evaluate Initiation of Stalevo in Early Wearing-off; ODM derived from: https://clinicaltrials.gov/show/NCT00462007

Link

https://clinicaltrials.gov/show/NCT00462007

Trefwoorden

Versies (1)
  1. 01-06-17 01-06-17 -
Geüploaded op

1 juni 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Parkinson's Disease NCT00462007

Engels

Eligibility Parkinson's Disease NCT00462007

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects with idiopathic parkinson's disease and early wearing-off symptoms treated with standard levodopa/ddci treatment
Beschrijving

Parkinson Disease | Levodopa | DOPA Decarboxylase Inhibitors | Wearing off effect Early

Datatype

boolean

Alias
UMLS CUI [1]
C0030567
UMLS CUI [2]
C0023570
UMLS CUI [3]
C0598272
UMLS CUI [4,1]
C1504539
UMLS CUI [4,2]
C1279919
age >35 - years
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
hoehn and yahr stage 1-3 performed during the 'on'-stage
Beschrijving

Hoehn and Yahr Stage | Pharmaceutical Preparations Use of

Datatype

boolean

Alias
UMLS CUI [1]
C3639483
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1524063
at least 1 symptom identified by woq-9
Beschrijving

Symptoms Quantity Identified Wearing off Questionnaire

Datatype

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0205396
UMLS CUI [1,4]
C1504539
UMLS CUI [1,5]
C0034394
dosing frequency of 3-4 doses of standard-release levodopa/ddci (maximum total daily dose of 600 mg of levodopa)
Beschrijving

Levodopa Dose U/day Maximum | DOPA Decarboxylase Inhibitors Dose Frequency

Datatype

boolean

Alias
UMLS CUI [1,1]
C0023570
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0456683
UMLS CUI [1,4]
C0806909
UMLS CUI [2,1]
C0598272
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0439603
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
atypical or symptomatic parkinson's disease
Beschrijving

Atypical Parkinson Disease | Secondary Parkinson Disease

Datatype

boolean

Alias
UMLS CUI [1]
C1868596
UMLS CUI [2]
C0030569
unpredictable off-periods
Beschrijving

UPDRS - Off Periods Unpredictable

Datatype

boolean

Alias
UMLS CUI [1]
C3639872
any peak-dose dyskinesia. 'off'-state dystonia is allowed
Beschrijving

Dyskinetic syndrome Peak Dose | Dystonia Pharmaceutical Preparations Off

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013384
UMLS CUI [1,2]
C0444505
UMLS CUI [1,3]
C0178602
UMLS CUI [2,1]
C0013421
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C1518543
use of any rescue medications to treat symptoms of 'off'-state. 1 dose of soluble levodopa/ddci is allowed.
Beschrijving

Pharmaceutical Preparations Additional | Levodopa Dose Quantity | DOPA Decarboxylase Inhibitors Dose Quantity

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1524062
UMLS CUI [2,1]
C0023570
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C1265611
UMLS CUI [3,1]
C0598272
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C1265611
concomitant treatment with non-selective monoamine oxidase (mao) inhibitor or simultaneous use of higher than recommended doses of mao-a and mao-b inhibitors (selegiline 10 mg or rasagiline 1 mg allowed) or use of apomorphine.
Beschrijving

Monoamine oxidase inhibitors, non-selective | Monoamine Oxidase-A Inhibitors High dose | Monoamine Oxidase-B Inhibitors High dose | Selegiline Dose | Rasagiline Dose | Apomorphine

Datatype

boolean

Alias
UMLS CUI [1]
C3653330
UMLS CUI [2,1]
C2917289
UMLS CUI [2,2]
C0444956
UMLS CUI [3,1]
C2917290
UMLS CUI [3,2]
C0444956
UMLS CUI [4,1]
C0036579
UMLS CUI [4,2]
C0178602
UMLS CUI [5,1]
C0525678
UMLS CUI [5,2]
C0178602
UMLS CUI [6]
C0003596
Terug naar het begin van de pagina

Similar models

Eligibility Parkinson's Disease NCT00462007

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Parkinson Disease | Levodopa | DOPA Decarboxylase Inhibitors | Wearing off effect Early
Item
subjects with idiopathic parkinson's disease and early wearing-off symptoms treated with standard levodopa/ddci treatment
boolean
C0030567 (UMLS CUI [1])
C0023570 (UMLS CUI [2])
C0598272 (UMLS CUI [3])
C1504539 (UMLS CUI [4,1])
C1279919 (UMLS CUI [4,2])
Age
Item
age >35 - years
boolean
C0001779 (UMLS CUI [1])
Hoehn and Yahr Stage | Pharmaceutical Preparations Use of
Item
hoehn and yahr stage 1-3 performed during the 'on'-stage
boolean
C3639483 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
Symptoms Quantity Identified Wearing off Questionnaire
Item
at least 1 symptom identified by woq-9
boolean
C1457887 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0205396 (UMLS CUI [1,3])
C1504539 (UMLS CUI [1,4])
C0034394 (UMLS CUI [1,5])
Levodopa Dose U/day Maximum | DOPA Decarboxylase Inhibitors Dose Frequency
Item
dosing frequency of 3-4 doses of standard-release levodopa/ddci (maximum total daily dose of 600 mg of levodopa)
boolean
C0023570 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0806909 (UMLS CUI [1,4])
C0598272 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0439603 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Atypical Parkinson Disease | Secondary Parkinson Disease
Item
atypical or symptomatic parkinson's disease
boolean
C1868596 (UMLS CUI [1])
C0030569 (UMLS CUI [2])
UPDRS - Off Periods Unpredictable
Item
unpredictable off-periods
boolean
C3639872 (UMLS CUI [1])
Dyskinetic syndrome Peak Dose | Dystonia Pharmaceutical Preparations Off
Item
any peak-dose dyskinesia. 'off'-state dystonia is allowed
boolean
C0013384 (UMLS CUI [1,1])
C0444505 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0013421 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C1518543 (UMLS CUI [2,3])
Pharmaceutical Preparations Additional | Levodopa Dose Quantity | DOPA Decarboxylase Inhibitors Dose Quantity
Item
use of any rescue medications to treat symptoms of 'off'-state. 1 dose of soluble levodopa/ddci is allowed.
boolean
C0013227 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0023570 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0598272 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Monoamine oxidase inhibitors, non-selective | Monoamine Oxidase-A Inhibitors High dose | Monoamine Oxidase-B Inhibitors High dose | Selegiline Dose | Rasagiline Dose | Apomorphine
Item
concomitant treatment with non-selective monoamine oxidase (mao) inhibitor or simultaneous use of higher than recommended doses of mao-a and mao-b inhibitors (selegiline 10 mg or rasagiline 1 mg allowed) or use of apomorphine.
boolean
C3653330 (UMLS CUI [1])
C2917289 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
C2917290 (UMLS CUI [3,1])
C0444956 (UMLS CUI [3,2])
C0036579 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0525678 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0003596 (UMLS CUI [6])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial